CDT Equity (CDT) vs China SXT Pharmaceuticals (SXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
China SXT Pharmaceuticals is the larger company by market cap ($453,907 vs $32,432), about 14.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDT | SXTC |
|---|---|---|
| Share price | $0.80 | $0.3435 |
| Market cap | $32.43K | $453.91K |
| 1-day change | -4.31% | -87.86% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $90,812.50 | $-730.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28,400.00 | $83,760.00 |
| 52-week low | $0.796 | $0.31 |
| Distance from 52-week high | -100.00% | -100.00% |
| Average volume | 188.27K | 4.71M |
| Shares outstanding | 40.54K | 1.32M |
| Employees | 4 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- China SXT Pharmaceuticals is about 14.0 times larger than CDT Equity by market value ($453.91K vs $32.43K).
About CDT Equity
CDT stock →CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About China SXT Pharmaceuticals
SXTC stock →China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
CDT vs SXTC FAQ
Which is bigger, CDT Equity or China SXT Pharmaceuticals?
China SXT Pharmaceuticals (SXTC) is larger, with a market capitalization of $453.91K compared with $32.43K for CDT Equity (CDT).
Are CDT Equity and China SXT Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.